{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-011546","form_type":"8-K","ticker":"INCY","cik":"0000879169","company_name":"INCYTE CORP","filed_at":"2022-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.404948+00:00","generated_at":"2026-06-24T06:12:30.443023+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Incyte Q2 total revenues up 29% to $911M; raises Jakafi guidance bottom end","bullets":["Total revenues $911M (+29% YoY); product revenues $664M (+15% YoY).","Jakafi net product revenues $598M (+13% YoY); FY guidance raised to $2.36-$2.40B.","GAAP diluted EPS $0.72; Non-GAAP diluted EPS $1.01 (up from $0.80 YoY).","Opzelura approved for vitiligo in July; ~48,000 units shipped in Q2 in atopic dermatitis launch.","Itacitinib development in chronic GVHD halted; pivotal trial deemed unlikely to succeed."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-011546","json":"https://secwatch.observer/filing/0001558370-22-011546.json","markdown":"https://secwatch.observer/filing/0001558370-22-011546.md","text":"https://secwatch.observer/filing/0001558370-22-011546.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879169/000155837022011546/0001558370-22-011546-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879169/000155837022011546/incy-20220802x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T06:12:30.443023+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}